Introduction
At the end of the 1970s a lactobacillus vaccine, SolcoTrichovac, was introduced by the Swiss company, Solco (Basel), as a new treatment of urogenital trichomoniasis in man. The systemic vaccine, which consists of eight inactivated aberrant strains of Lactobacillus acidophilus isolated from patients infected with Trichomonas vaginalis, should represent an alternative to nitroimidazole chemotherapy. According to various authors, the efficacy of SolcoTrichovac immunotherapy is 90-100%. ' Hungarian workers first reported attempts to control urogenital trichomoniasis by immunisation with inactivated lactobacilli, which were isolated either from patients with trichomoniasis or from healthy virgins.2 As with streptococcal3 or trichomonal vaccines,2 [4] [5] [6] Solco Trichovac was more effective at resolving clinical signs than in reducing the number of parasites in the vagina.
The precise mode of action of the bacterial vaccines against trichomoniasis is poorly understood. The hypothesis proposed by the makers of SolcoTrichovac is that the vaccine induces cross reacting antibodies against abnormal lactobacilli and T vaginalis without adversely affecting the growth of normal lactobacilli in the vagina. Clinical improvement as well as the elimination of Tvaginalis should therefore occur in the course of vaccination.7
The concept of antigenic similarity of two such unrelated and serologically variable groups of organisms as lactobacilli and trichomonads is rather surprising. The aim of the present study was therefore to assess the serological cross reactivity between lactobacilli from SolcoTrichovac vaccine and T vaginalis. Control slides were prepared using tested serum samples without conjugate and using conjugate without tested serum.
Indirect haemagglutination assay Fresh sheep erythrocytes were centrifuged at 800 x g for 10 minutes and washed three times in PBS. A 2 5% suspension of erythrocytes was mixed with an equal volume of tannic acid (diluted 1:120 000 in PBS) and incubated in an ice bath for 15 minutes. After being centrifuged at 800 x g for 10 minutes and washed repeatedly in PBS, the sediment was incubated with an equal volume of soluble trichomonal antigen for 15 minutes at 37°C. Sensitised erythrocytes were washed in PBS and diluted to a 2 5% suspension in PBS.
We used a modification of the tube assay described 
Discussion
According to the manufacturers of the lactobacillus vaccine Solco Trichovac, its immunotherapeutic effect in trichomoniasis is accomplished by stimulation of the specific immune response in the serum and probably also in the cervical secretion of the host. The mode of action of the vaccine, as claimed by the producers, is the induction of antibodies against aberrant L acidolphilus, which cross react with T vaginalis but not with physiological Doederlein's bacillus.7 1 ' 14 An increase in specific antilactobacillus agglutinins has been reported during the course of vaccination,'5 but few data supporting the presence of cross reacting antibodies have yet been presented. The only evidence of common antigens in T vaginalis and L acidophilus has been obtained by Stojkovic' 16 and Bonilla-Musoles et al'7 using indirect immunofluorescence assays.
In our experiments we failed to show any antigenic relation between lactobacilli from SolcoTrichovac In our experiments we recorded only a slight increase in titre of specific antibodies against L acidophilus in both human and rabbit serum after vaccination with SolcoTrichovac. This finding confirms the low immunogenicity of lactobacilli. 21 As both L acidophilus and T vaginalis occur in numerous serotypes,2 123 similarity of the two organisms seems to be very unlikely. Moreover, Doederlein flora comprise several species of lactobacillus, with interspecific as well as intraspecific serological differences. 2425 Our results and the data discussed above do not support the claim of the manufacturers of SolcoTrichovac. Nevertheless, the clinical effect reported so far is remarkable.' If it is confirmed, a different explanation for the mode of action of the vaccine will have to be sought by further investigations of the microbial interactions in the vagina as well as of the antigenic relations of the indiviual microorganisms.
